Welcome members and clients of OMMP PIF. Due to increased costs, our website has moved to this server, Thanks go to our Friend and colleague, Wired57, for making this possible. If you have any questions or concerns, please start a new topic in 
Thank you 
12-07-2016, 12:22 AM
Placebo-controlled, Double Blind Trial of Medicinal Cannabis in Painful HIV NeuropathyINVESTIGATOR: Ronald Ellis, M.D., Ph.D.
STUDY LOCATION: University of California, San Diego
PROJECT TITLE: Placebo-controlled, Double Blind Trial of Medicinal Cannabis in Painful HIV Neuropathy
PROJECT TYPE: Clinical Study
STATUS: COMPLETE
RESULTS:
Of 127 volunteers screened, 34 eligible subjects enarolled and 28 completed both cannabis and placebo treatments. Among completers, pain relief was greater with cannabis than placebo (median difference in DDS pain intensity change, 3.3 points, effect size = 0.60; p = 0.016). The proportions of subjects achieving at least 30% pain relief with cannabis versus placebo were 0.46 [95% CI 0.28, 0.65] and 0.18 [0.03, 0.32]. Mood and daily functioning improved to a similar extent during both treatment periods. Although most side effects were mild and self-limited, two subjects experienced treatment-limiting toxicities.
Smoked cannabis was generally well-tolerated and effective when added to concomitant analgesic therapy in patients with medically refractory pain due to HIV DSPN.
The full results of this study were published in the journal <a data-ipb="nomediaparse" href="http://www.ncbi.nlm.nih.gov/pubmed/18688212">Neuropsychopharmacology.</a>
ABSTRACT:
Neuropathic pain continues to be a major clinical problem in HIV infection. The predominant cause is an axonal polyneuropathy, termed HIV-associated distal, sensory-predominant polyneuropathy (DSPN) that is variably associated with HIV itself or with the use of certain nucleoside analogue HIV reverse transcriptase,....
<a data-ipb="nomediaparse" href="http://www.cmcr.ucsd.edu/index.php/2015-11-20-20-52-15/completed-studies/32-placebo-controlled-double-blind-trial-of-medicinal-cannabis-in-painful-hiv-neuropathy">http://www.cmcr.ucsd.edu/index.php/2015-11-20-20-52-15/completed-studies/32-placebo-controlled-double-blind-trial-of-medicinal-cannabis-in-painful-hiv-neuropathy</a>
STUDY LOCATION: University of California, San Diego
PROJECT TITLE: Placebo-controlled, Double Blind Trial of Medicinal Cannabis in Painful HIV Neuropathy
PROJECT TYPE: Clinical Study
STATUS: COMPLETE
RESULTS:
Of 127 volunteers screened, 34 eligible subjects enarolled and 28 completed both cannabis and placebo treatments. Among completers, pain relief was greater with cannabis than placebo (median difference in DDS pain intensity change, 3.3 points, effect size = 0.60; p = 0.016). The proportions of subjects achieving at least 30% pain relief with cannabis versus placebo were 0.46 [95% CI 0.28, 0.65] and 0.18 [0.03, 0.32]. Mood and daily functioning improved to a similar extent during both treatment periods. Although most side effects were mild and self-limited, two subjects experienced treatment-limiting toxicities.
Smoked cannabis was generally well-tolerated and effective when added to concomitant analgesic therapy in patients with medically refractory pain due to HIV DSPN.
The full results of this study were published in the journal <a data-ipb="nomediaparse" href="http://www.ncbi.nlm.nih.gov/pubmed/18688212">Neuropsychopharmacology.</a>
ABSTRACT:
Neuropathic pain continues to be a major clinical problem in HIV infection. The predominant cause is an axonal polyneuropathy, termed HIV-associated distal, sensory-predominant polyneuropathy (DSPN) that is variably associated with HIV itself or with the use of certain nucleoside analogue HIV reverse transcriptase,....
<a data-ipb="nomediaparse" href="http://www.cmcr.ucsd.edu/index.php/2015-11-20-20-52-15/completed-studies/32-placebo-controlled-double-blind-trial-of-medicinal-cannabis-in-painful-hiv-neuropathy">http://www.cmcr.ucsd.edu/index.php/2015-11-20-20-52-15/completed-studies/32-placebo-controlled-double-blind-trial-of-medicinal-cannabis-in-painful-hiv-neuropathy</a>